<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565145</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202001129</org_study_id>
    <secondary_id>IRB201900074-N</secondary_id>
    <secondary_id>1R61AT009988-01A1</secondary_id>
    <secondary_id>OCR36443</secondary_id>
    <secondary_id>3R61AT009988-02S1</secondary_id>
    <nct_id>NCT04565145</nct_id>
  </id_info>
  <brief_title>Biomarker Changes and Anxiolytic Effects-Phase 2</brief_title>
  <acronym>KavaPK</acronym>
  <official_title>A Phased Clinical Trial of a Dietary Supplement Kava: Biomarker Changes and Anxiolytic Effects Phase 2: Kava Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thorne Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic&#xD;
      properties of kava. The investigators will conduct a one week, double blind, randomized&#xD;
      placebo controlled trial of kava, dosed at three 75 mg capsules per day, vs placebo, in&#xD;
      adults with generalized anxiety disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic&#xD;
      properties of kava, a natural dietary supplement. The investigators will conduct a one week,&#xD;
      double blind, randomized placebo controlled trial of kava, dosed at three 75 mg capsules per&#xD;
      day, vs placebo, in adults with generalized anxiety disorder. Clinical measures of anxiety,&#xD;
      blood, and urine will be obtained. Biomarkers of interest include PRKACA, cortisol, urinary&#xD;
      TCE, and NA5HT. Participants will be assessed pre- and post-treatment. The participants will&#xD;
      also be followed for 12 weeks after the end of treatment to identify any potential rare&#xD;
      adverse events, particularly liver toxicity, that appear in a delayed fashion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean PRKACA change to validate PRKACA change %</measure>
    <time_frame>From Baseline up to Study Completion Date, an average of 1 year</time_frame>
    <description>To measure the mean PRKACA change to validate PRKACA change % of biomarkers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Kava Pharmacokinetics Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg kava dietary supplement capsules per day for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three placebo capsule per day for one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kava Dietary Supplement</intervention_name>
    <description>Participants will be given three 75mg kava capsules per day for one week</description>
    <arm_group_label>Kava Pharmacokinetics Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be given three placebo capsules per day for one week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ages 18-50 who meet DSM-5 criteria for GAD as the primary psychiatric diagnosis&#xD;
&#xD;
          -  No more than one failed therapeutic trial of an FDA approved medication for the&#xD;
             treatment of GAD&#xD;
&#xD;
          -  Score of&gt;14 on the Hamilton Anxiety Rating Scale at both screening and baseline&#xD;
&#xD;
          -  At least a 4 (moderate) on the Clinical Global Impressions Severity Scale at both&#xD;
             screening and baseline&#xD;
&#xD;
          -  Females of potential childbearing status must use adequate contraceptive precautions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling/unable/unsafe to stop psychotropic medications (if on any) for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Inability to refrain from acetaminophen, alcohol or other potentially hepatotoxic&#xD;
             substances&#xD;
&#xD;
          -  History of liver disease or current liver disease or clinically significant elevation&#xD;
             in serum liver chemistries&#xD;
&#xD;
          -  Unstable medical or neurological condition&#xD;
&#xD;
          -  Positive urine drug screen for substances of abuse&#xD;
&#xD;
          -  Active substance abuse/dependence&#xD;
&#xD;
          -  Lifetime history of a psychotic disorder, bipolar disorder, PTSD or OCD&#xD;
&#xD;
          -  Any significant risk for self-harm or suicidality as determined by the principal&#xD;
             investigator or suicide attempt within the last 6 months&#xD;
&#xD;
          -  Psychotherapy newly instituted during the 6 weeks leading up to enrollment in the&#xD;
             study. Subjects established in psychotherapy without change during the course of the&#xD;
             study may participate&#xD;
&#xD;
          -  Montgomery-Asberg Depression Rating Scale (MADRS) &gt; 17 (moderate or severe depressive&#xD;
             symptoms)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robyn Nelson</last_name>
    <phone>352-294-5563</phone>
    <email>r.nelson@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF CTSI Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carol Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chengguo Xing, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kava</keyword>
  <keyword>dietary supplement</keyword>
  <keyword>anxiety</keyword>
  <keyword>generalized anxiety disorder (GAD)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

